Spyros Papapetropoulos

Insider Reports History

Identity Names, identifiers, and filing context for this profile. 1 identity field
Reporting-owner location
Emeryville, CA
SEC source record Original filing metadata and source links for verification. 1 source field
Latest reporting-owner signature
/s/ Spyros Papapetropoulos
Source: Latest parsed Forms 3/4/5 signature
Source evidence Original filing metadata and source links for verification. 1 source field
Transaction source note
Rows are grouped by transaction date from the original SEC filing. Open the aggregated insider activity page to review issuer-level activity across dates.

Reported holdings for Spyros Papapetropoulos

Form 4 holding President and CEO, Director

Neuphoria Therapeutics Inc.

Security class
Employee Stock Option (Right-to- Buy)
Shares / value
74,088
Estimated value
$612,707
Report date
27 Aug 2025
Price
$8.27
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding Director

Lipocine Inc.

Security class
Stock Option (Right to Buy)
Shares / value
7,174
Estimated value
$22,956
Report date
04 Jun 2025
Price
$3.20
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding Chief Medical Officer

Vigil Neuroscience, Inc.

Security class
Common Stock
Shares / value
4,000
Estimated value
$15,000
Report date
18 Nov 2022
Price
$3.75
Ownership
Direct
Form 4 holding Chief Medical Officer

Vigil Neuroscience, Inc.

Security class
Stock Option Grant (Right to Buy)
Shares / value
149,604
Estimated value
Report date
18 Nov 2022
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding Director

Adamas Pharmaceuticals Inc

Security class
Stock Option (Right to Buy)
Shares / value
0
Estimated value
Report date
24 Nov 2021
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount

Insider Reports Filed by Spyros Papapetropoulos

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .